News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Kyle Todd Shared New White Paper Analyzing Clinical Development Trends Across 594 ADCs with 142 Distinct Targets
Kyle Todd/LinkedIn
Jun 25, 2025, 14:17

Kyle Todd Shared New White Paper Analyzing Clinical Development Trends Across 594 ADCs with 142 Distinct Targets

Kyle Todd, Founder and CEO of Zeal Oncology, shared a post on LinkedIn:

“Antibody-Drug Conjugates (ADCs): Expanding the Oncology Target Space
ADCs are no longer trailing traditional antibody therapeutics – they’re leading innovation across oncology, unlocking novel targets, and advancing through clinical development with increasingly sophisticated payloads and formats.
This white paper analyzes clinical development trends across 594 ADCs with 142 distinct targets, highlighting how ADCs are:
• Outpacing other modalities for select targets
• Pursuing targets untouched by other therapeutic classes
• Innovating beyond canonical payloads and antibody formats
Download the full white paper below and follow Zeal Oncology for more insights across the cancer therapeutic landscape!”

Clinical Development

More posts featuring Antibody-Drug Conjugates on OncoDaily.

Antibody Drug Conjugates (ADCs) cancer Kyle Todd OncoDaily Oncology Zeal Oncology
Special Coverage
Blog
Jun 25, 2025, 14:17
Kyle Todd Shared New White Paper Analyzing Clinical Development Trends Across 594 ADCs with 142 Distinct Targets
Blog
Jun 25, 2025, 14:06
Renjith Vijayakumar Selvarani: An Indian-based startup OLUSIUM is breaking new ground in cancer diagnostics
Insight
Jun 25, 2025, 13:56
Loay Kassem Announced the Launch of "Not Her Journey Alone" Breast Cancer Educational Series with AstraZeneca Egypt
Career
Jun 25, 2025, 13:47
Nitin Yashas Murthy Joins Manipal Hospital Kanakpura Road as Medical Oncologist and Hemato-Oncologist
Blog
Jun 25, 2025, 13:24
Join EIOC on 26th June to Explore Breast Cancer Updates from ASCO 2025
Blog
Jun 25, 2025, 13:02
Andreas Charalambous Highlights MASCC Board Session in Seattle - Strategic Vision for Supportive Care
Science
Jun 25, 2025, 12:45
Elizabeth McKenna: New Studies on KAT6/7 Histone Acetyltransferase as Therapeutic Targets in AML Published in Cancer Discovery
Blog
Jun 25, 2025, 12:26
Despite Improvements in Cancer Care: Stakeholder Policy Forum on Persisting Challenges in Cyprus - ECO
Blog
Jun 25, 2025, 12:09
Apply for AACR James Ewing-Thelma Dunn Award for Outstanding Achievement in Pathology in Cancer Research by June 30
Oncolibrary
Jun 25, 2025, 10:27
The Day After a Nuclear Bomb: Generational Damage and the Silent Cancer Epidemic
Blog
Jun 25, 2025, 10:00
Scientific Advisory Board Members - World Bladder Cancer Patient Coalition
Science
Jun 25, 2025, 09:58
Prerna Mewawalla: Excited to Share our Multicenter Study on Real-world Outcomes of Sequential BCMA Therapies in RRMM After Belantamab